礼邦医药-B(09637)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09637 礼邦医药-B

未开盘 10-21 16:08:18

16.980

+0.110

+0.65%

最高19.330	最低16.900	成交量257.33万
今开18.000	昨收16.870	日振幅14.40%
总市值59.09亿	流通市值40.07亿	总股本3.48亿
成交额4,650万	换手率1.09%	流通股本2.36亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09637","market":"HK","secType":"STK","nameCN":"礼邦医药-B","latestPrice":16.98,"timestamp":1792570098928,"preClose":16.87,"halted":0,"volume":2573300,"delay":0,"changeRate":0.006520450503852959,"floatShares":236000000,"shares":348000000,"eps":-3.071284,"marketStatus":"未开盘","change":0.11,"latestTime":"10-21 16:08:18","open":18,"high":19.33,"low":16.9,"amount":46499007,"amplitude":0.144043,"askPrice":16.98,"askSize":400,"bidPrice":16.95,"bidSize":400,"shortable":0,"etf":0,"ttmEps":-2.326,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792632600000},"marketStatusCode":0,"adr":0,"listingDate":1782662400000,"exchange":"SEHK","adjPreClose":16.87,"openAndCloseTimeList":[[1792546200000,1792555200000],[1792558800000,1792569600000]],"volumeRatio":1.1876427554261995,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09637/wiki","defaultTab":"wiki","newsList":[{"id":"2677446643","title":"港股异动 | 礼邦医药-B(09637.HK)高开逾6% 拟在公开市场购回H股 总金额不超过1亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677446643","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677446643?lang=zh_cn&edition=full","pubTime":"2026-10-21 09:25","pubTimestamp":1792545914,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1161","09637","BK1515","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676769362","title":"礼邦医药-B(09637)拟回购不超过1亿港元H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2676769362","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676769362?lang=zh_cn&edition=full","pubTime":"2026-10-20 20:08","pubTimestamp":1792498138,"startTime":"0","endTime":"0","summary":"智通财经APP讯，礼邦医药-B 公布，董事会已议决根据于2026年8月14日举行的临时股东会上经公司股东批准并授予公司董事的一般授权，不时于香港联合交易所有限公司公开市场购回公司H股，总金额不超过1亿港元。经考虑H股的交易表现、公司的业务及财务状况、资金需求以及股东的整体利益，董事会认为股份购回属必要及合理。在届时可获得的适用股份购回授权范围内，公司或会根据市况进一步购回H股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1509682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1161","09939","159938","BK1574","BK1515","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157050182","title":"礼邦医药-B(09637)获授权回购不超过1亿港元H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1157050182","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157050182?lang=zh_cn&edition=full","pubTime":"2026-10-20 20:06","pubTimestamp":1792497973,"startTime":"0","endTime":"0","summary":"10月20日，礼邦医药-B发布自愿公告称，董事会已议决在香港联交所场内回购公司H股，累计支付总额不超过1亿港元。本次回购基于2026年8月14日召开的临时股东会上获通过的一般性股份回购授权。董事会表示，回购目的在于维护公司价值及股东利益。公司提醒股东及潜在投资者，是否回购及具体规模将视乎市况，由董事会及其授权人士决定，不保证任何回购的时间、数量或价格。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676187653","title":"礼邦医药-B早盘一度飙升逾47% AP308获FDA临床许可及国内受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2676187653","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676187653?lang=zh_cn&edition=full","pubTime":"2026-10-20 10:22","pubTimestamp":1792462920,"startTime":"0","endTime":"0","summary":"模拟交易客户端10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。礼邦医药-B早盘一度飙升逾47%。截至发稿，股价回落现涨11.04%，报19.41港元，成交额8187.61万港元。北大医院近日宣布，其肾脏内科与礼邦医药联合开发的新一代AP308/PKU308用于治疗IgA肾病的新药临床试验申请获美国FDA批准，即将进入首次人体临床研究阶段。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-10-20/doc-inivvsvt5849002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","LABU","BK1191","BK4585","09939","159938","BK1161","BK1574","09637","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676665806","title":"港股异动 | 礼邦医药-B(09637.HK)飙升逾46% AP308获FDA临床许可及国内受理 全球化布局价值有望兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2676665806","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676665806?lang=zh_cn&edition=full","pubTime":"2026-10-20 10:03","pubTimestamp":1792461837,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","BK1191","09637","BK1161","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675563356","title":"港股异动 | 礼邦医药-B(09637.HK)盘中一度涨近4% 振幅达13.53% 港股创新药板块集体走强 AP308治疗IgA肾病新药临床试验获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2675563356","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675563356?lang=zh_cn&edition=full","pubTime":"2026-10-16 12:47","pubTimestamp":1792126069,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","09637","BK1574","BK1515","BK1161","06978","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673062289","title":"港股异动 | 礼邦医药-B(09637)早盘涨近7% 机构指AP308有望解锁更加广阔的IgA肾病市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2673062289","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673062289?lang=zh_cn&edition=full","pubTime":"2026-10-07 11:00","pubTimestamp":1791342052,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，礼邦医药-B早盘涨近7%。截至发稿，涨2.78%，报27.4港元，成交额641.32万港元。消息面上，礼邦医药近期发布公告，其工程化重组IgA蛋白酶AP308用于治疗IgA肾病的新药临床试验申请获美国FDA批准，公司计划近期启动首次人体临床试验。按公司公告表述，AP308为已知首个获准开展临床试验的IgA蛋白酶类IgAN候选药物。尤其AP308若能验证能够实现IgA肾病的功能性治愈，则有望解锁更加广阔的IgA肾病市场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504116.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1161","BK1515","BK1191","BK4585","09637","BK1574","09939","VXUS","KCAI","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673543290","title":"五连涨，阶段低点以来跑赢恒指18.5个百分点：肾脏病的风口来了","url":"https://stock-news.laohu8.com/highlight/detail?id=2673543290","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673543290?lang=zh_cn&edition=full","pubTime":"2026-10-06 21:49","pubTimestamp":1791294554,"startTime":"0","endTime":"0","summary":"截至10月6日收盘，礼邦医药报26.66港元，录得五连涨，较9月28日收盘累计上涨13.7%。按9月14日23港元的阶段收盘低点起算，累计反弹15.9%；同期恒生指数下跌2.6%，跑赢约18.5个百分点。共同病理机制、多适应症开发与全球权益，让AP303成为礼邦拓展肾脏病治疗版图的重要支点。全球IIb期多区域临床试验已完成首例受试者随机化并给药。五连涨背后值得关注的，是肾脏病行业的新机制、商业化增量与公司自身管线进展开始形成呼应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504041.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165566387","title":"礼邦医药-B更新2026年9月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1165566387","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165566387?lang=zh_cn&edition=full","pubTime":"2026-10-06 16:49","pubTimestamp":1791276570,"startTime":"0","endTime":"0","summary":"礼邦医药(江蘇)股份有限公司于2026年10月6日发布了截至2026年9月30日止当月的股份变动月报表。公告显示，公司注册股本合计为人民币348,365,531元，其中包括已在香港联交所上市的H股普通股235,635,489股，每股面值人民币1元，内资股普通股112,730,042股，每股面值人民币1元。上述各类注册股本在2026年9月期间均无新增或减少，维持不变。礼邦医药-B表示，截至本月末，其上市H股的公众持股比例符合香港联交所相关上市规则及最低公众持股量的要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671296172","title":"港股异动 | 礼邦医药-B(09637.HK)午后涨近8% AP308/PKU308获美国FDA临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2671296172","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671296172?lang=zh_cn&edition=full","pubTime":"2026-09-29 14:40","pubTimestamp":1790664029,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1574","BK1161","09939","BK1515","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669130755","title":"港股异动 | 礼邦医药-B(09637.HK)涨超8% AP308治疗IgAN新药申请获FDA批准 已于肾脏医学领域验证治疗潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2669130755","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669130755?lang=zh_cn&edition=full","pubTime":"2026-09-21 14:12","pubTimestamp":1789971124,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","09637","BK1191","BK1574","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173874044","title":"礼邦医药-B 2026年中期财报：营收1.04亿元，经调整净亏损1.30亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1173874044","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173874044?lang=zh_cn&edition=full","pubTime":"2026-09-17 20:42","pubTimestamp":1789648920,"startTime":"0","endTime":"0","summary":"2026年上半年，礼邦医药-B录得营业收入1.04亿元，同比上升761.2%。经调整净亏损1.30亿元，相比上年同期的1.49亿元减亏12.6%。同期毛利约0.91亿元，毛利率从上年同期的43.4%提升至87.5%。报告期内，研发开支为1.41亿元，同比增长28.4%，占营业收入的比重约为135.7%。销售及管理费用均有不同程度提升，其中销售开支同比增长20.7%，管理费用则增长108.9%。经营活动现金流方面，本期净流出约1.85亿元，较上年同期的1.39亿元净流出规模扩大。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"礼邦医药-B 2026年中期财报：营收1.04亿元，经调整净亏损1.30亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667619385","title":"港股异动 | 礼邦医药-B(09637)午后飙升逾17% AP308治疗IgA肾病新药临床申请获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667619385","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667619385?lang=zh_cn&edition=full","pubTime":"2026-09-15 13:36","pubTimestamp":1789450580,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，礼邦医药-B午后飙升逾17%。消息面上，礼邦医药近日宣布，AP308用于治疗IgA肾病的新药临床试验申请近日获美国食品药品监督管理局批准。公司计划于近期启动AP308的首次人体临床试验。AP308的IND获批标志着这一首创新药由临床前研究迈入临床开发阶段。公告指出，IgA肾病是全球最常见的原发性肾小球肾炎，2025年全球患者约950万人，其中中国约510万人，占全球过半。约60%中国患者于确诊后15年内进展至终末期肾病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LABU","BK1515","BK4588","BK4585","159938","09637","BK1191","KCAI","09939","BK1574","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165566607","title":"礼邦医药-B获美国FDA批准AP308新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1165566607","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165566607?lang=zh_cn&edition=full","pubTime":"2026-09-08 23:32","pubTimestamp":1788881551,"startTime":"0","endTime":"0","summary":"9月8日（路透社）——礼邦医药-B（Alebund Pharmaceuticals (Jiangsu) Ltd，股票代码：9637.HK）今日发布公告，其用于治疗IgA肾病的在研新药AP308的临床试验申请（IND）已获得美国食品药品监督管理局（FDA）的批准。这一里程碑式的进展，标志着礼邦医药在肾脏疾病领域的创新药物研发管线迈出了关键一步，为其后续的临床开发铺平了道路。随着该申请的获批，礼邦医药将得以在美国推进AP308的临床研究计划，进一步评估其安全性和有效性。此次FDA的放行，不仅为AP308的全球多中心临床试验奠定了基础，也为公司在该适应症领域的长期布局注入了强劲动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378596","title":"礼邦医药-B：AP308治疗IgA肾病新药临床申请获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378596","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665378596?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:20","pubTimestamp":1788870000,"startTime":"0","endTime":"0","summary":"9月8日，礼邦医药-B（09637）发布公告，公司自主研发的同类首创工程化重组IgA蛋白酶AP308，其新药临床试验申请已获FDA批准，将启动用于治疗IgA肾病的首次人体临床试验。公告指出，IgA肾病是全球最常见的原发性肾小球肾炎，2025年全球患者约950万人，其中中国约510万人，占全球过半。约60%中国患者于确诊后15年内进展至终末期肾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609083868261729.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609083868261729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1515","159938","09939","09637","BK1574","BK4585","BK1191","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112664296","title":"礼邦医药-B（09637）AP308获美国FDA临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1112664296","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112664296?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:12","pubTimestamp":1788869569,"startTime":"0","endTime":"0","summary":"2026年9月8日，礼邦医药（江苏）股份有限公司公告称，其同类首创工程化重组IgA蛋白酶AP308的治疗性新药临床试验申请已获美国食品药品监督管理局批准，公司将启动AP308用于治疗IgA肾病的首次人体临床试验。据公司披露，AP308是首个获准开展临床试验的IgA蛋白酶类IgAN候选药物。公司持有AP308全球开发、生产及商业化权利。公司表示，将于近期启动AP308首次人体临床试验，以验证其在直接清除肾小球致病性IgA免疫复合物方面的安全性与疗效。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195070981","title":"礼邦医药-B：AP308治疗IgA肾病获美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1195070981","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195070981?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:01","pubTimestamp":1788868873,"startTime":"0","endTime":"0","summary":"礼邦医药（Jiangsu）近日宣布，其用于治疗IgA肾病的在研新药AP308已获得美国食品药品监督管理局（FDA）的临床试验申请批准。这一进展标志着该候选药物在研发进程中迈出了关键一步，为后续临床研究的推进铺平了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665349337","title":"港股异动 | 礼邦医药-B(09637.HK)涨超6% 纳入港股通及恒生综合指数落地 美信罗销售同比增约105% 商业化兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2665349337","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665349337?lang=zh_cn&edition=full","pubTime":"2026-09-08 10:16","pubTimestamp":1788833785,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","HSCI","BK1574","09939","BK1191","BK1515","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665398982","title":"礼邦医药-B公布H股获纳入港股通及恒生综合指数","url":"https://stock-news.laohu8.com/highlight/detail?id=2665398982","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665398982?lang=zh_cn&edition=full","pubTime":"2026-09-07 08:50","pubTimestamp":1788742200,"startTime":"0","endTime":"0","summary":"模拟交易客户端礼邦医药-B公布，据港股通的相关安排及调整，公司H股获纳入港股通合资格证券名单，将自2026年9月7日（星期一）起生效。H股获纳入港股通乃基于其获纳入恒生综合指数。董事会认为，H股获纳入港股通及恒生综合指数，反映了资本市场对公司价值及长期发展前景的认可，并将有助于进一步扩大公司的投资者基础，提升H股的交易流动性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-09-07/doc-iniqyeua9585261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HSCI","BK1161","BK1515","BK1574","159938","09939","09637","FLHK","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122886210","title":"礼邦医药-B（09637）H股获纳入港股通与恒生综合指数 9月7日生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1122886210","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122886210?lang=zh_cn&edition=full","pubTime":"2026-09-04 21:35","pubTimestamp":1788528943,"startTime":"0","endTime":"0","summary":"礼邦医药-B9月4日公告称，公司H股已被纳入港股通合资格证券名单，生效日期为2026年9月7日。届时，中国内地合资格投资者可通过港股通渠道直接买卖该公司H股。根据恒生指数有限公司于2026年8月21日公布的截至2026年6月30日的恒生指数系列季度检讨结果，礼邦医药-B H股已被纳入恒生综合指数成份股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alebund.com","stockEarnings":[{"period":"1week","weight":-0.2275},{"period":"1month","weight":-0.3655},{"period":"3month","weight":-0.394},{"period":"6month","weight":-0.2487},{"period":"ytd","weight":-0.2487}],"compareEarnings":[{"period":"1week","weight":-0.0272},{"period":"1month","weight":-0.0555},{"period":"3month","weight":-0.0618},{"period":"6month","weight":-0.0895},{"period":"1year","weight":-0.0913},{"period":"ytd","weight":-0.0772}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"礼邦医药（江苏）股份有限公司是一家主要从事生物制药的中国公司。该公司的临床及临床前产品组合由一款核心产品AP301及其他候选产品组成，包括：一款临床后期候选产品（AP306）、一款临床前期候选药物（AP303），以及四款临床前候选药物（AP308、AP304、AP305与AP307）。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"礼邦医药-B","nameEN":"ALEBUND-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"礼邦医药-B(09637)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供礼邦医药-B(09637)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"礼邦医药-B,09637,礼邦医药-B股票,礼邦医药-B股票老虎,礼邦医药-B股票老虎国际,礼邦医药-B行情,礼邦医药-B股票行情,礼邦医药-B股价,礼邦医药-B股市,礼邦医药-B股票价格,礼邦医药-B股票交易,礼邦医药-B股票购买,礼邦医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"礼邦医药-B(09637)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供礼邦医药-B(09637)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}